BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment
Share
Why It Matters
BeyondSpring got FDA fast track for a new lung cancer medicine. That means faster review, plus a deal to fund their China studies.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.